PE20180251A1 - PROTEINA DE UNIION A RGMa Y SU USO - Google Patents

PROTEINA DE UNIION A RGMa Y SU USO

Info

Publication number
PE20180251A1
PE20180251A1 PE2017002320A PE2017002320A PE20180251A1 PE 20180251 A1 PE20180251 A1 PE 20180251A1 PE 2017002320 A PE2017002320 A PE 2017002320A PE 2017002320 A PE2017002320 A PE 2017002320A PE 20180251 A1 PE20180251 A1 PE 20180251A1
Authority
PE
Peru
Prior art keywords
rgma
binding protein
seq
prevent
binding
Prior art date
Application number
PE2017002320A
Other languages
English (en)
Inventor
Motonori Hashimoto
Toshihide Yamashita
Original Assignee
Mitsubishi Tanabe Pharma Corp
Univ Osaka
Univ Chiba Nat Univ Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp, Univ Osaka, Univ Chiba Nat Univ Corp filed Critical Mitsubishi Tanabe Pharma Corp
Publication of PE20180251A1 publication Critical patent/PE20180251A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)

Abstract

Referido a una proteina de union a Molecula Guia Repelente A (RGMa aislada), que no inhibe la union entre la Molecula Guia Repelente a (RGMa) y neogenina pero neutraliza la actividad inhibidora del crecimiento neutritico de RGMa, preferiblemente proporcionando un anticuerpo anti-RGMa que tiene regiones determinantes de complementariedad que tienen secuencias de aminoacidos de SEQ ID NOS: 30-35 o SEQ ID NO: 36-40 en el listado de secuencias, y SFG. Utiles para prevenir, tratar o prevenir la recaida de enfermedades neurologicas o inmunologicas, tales como: lesion del plexo braquial, paralisis cerebral, esclerosis multiple, neuromielitis optica entre otros. Tambien se refiere a una composicion farmaceutica, una molecula de acido nucleico, un vector recombinante, una celula hospedera y un metodo para producir la proteina de union a RGM-a.
PE2017002320A 2015-04-28 2016-04-27 PROTEINA DE UNIION A RGMa Y SU USO PE20180251A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2015091095 2015-04-28

Publications (1)

Publication Number Publication Date
PE20180251A1 true PE20180251A1 (es) 2018-02-02

Family

ID=57198582

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2017002320A PE20180251A1 (es) 2015-04-28 2016-04-27 PROTEINA DE UNIION A RGMa Y SU USO
PE2022001997A PE20230381A1 (es) 2015-04-28 2016-04-27 Proteina de union a rgma

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2022001997A PE20230381A1 (es) 2015-04-28 2016-04-27 Proteina de union a rgma

Country Status (33)

Country Link
US (3) US10287346B2 (es)
EP (2) EP3290441B1 (es)
JP (8) JP6497760B2 (es)
KR (4) KR102451786B1 (es)
CN (2) CN107531791B (es)
AU (2) AU2016253886B2 (es)
CA (1) CA2983898A1 (es)
CL (1) CL2017002729A1 (es)
CO (1) CO2017011975A2 (es)
CR (2) CR20170539A (es)
CY (1) CY1122569T1 (es)
DK (1) DK3290441T3 (es)
DO (1) DOP2017000248A (es)
ES (1) ES2758480T3 (es)
GT (1) GT201700224A (es)
HR (1) HRP20192099T1 (es)
HU (1) HUE047146T2 (es)
IL (2) IL287291B (es)
LT (1) LT3290441T (es)
MX (2) MX392169B (es)
NZ (2) NZ775372A (es)
PE (2) PE20180251A1 (es)
PH (1) PH12017501941A1 (es)
PL (1) PL3290441T3 (es)
PT (1) PT3290441T (es)
RS (1) RS59847B1 (es)
RU (1) RU2705304C2 (es)
SA (1) SA517390230B1 (es)
SG (1) SG11201708848TA (es)
SI (1) SI3290441T1 (es)
TW (4) TWI873576B (es)
WO (1) WO2016175236A1 (es)
ZA (2) ZA201708047B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20180251A1 (es) * 2015-04-28 2018-02-02 Mitsubishi Tanabe Pharma Corp PROTEINA DE UNIION A RGMa Y SU USO
US20200087390A1 (en) 2016-12-21 2020-03-19 Amgen Inc. Anti-tnf alpha antibody formulations
WO2018215345A1 (en) * 2017-05-25 2018-11-29 Philips Lighting Holding B.V. Luminaire
BR112021000300A2 (pt) 2018-07-10 2021-04-06 Mitsubishi Tanabe Pharma Corporation Método de prevenção ou tratamento para neuropatia periférica ou doença acompanhada de dor em que neuropatia periférica ou transtorno de astrocito é reconhecido
US20210269535A1 (en) * 2018-07-19 2021-09-02 The University Of Tokyo Therapeutic or prophylactic agent for htlv-1-associated myelopathy (ham), and method for treating ham
AR120898A1 (es) 2019-12-26 2022-03-30 Univ Osaka Agente para tratar o prevenir neuromielitis óptica en fase aguda
JP7709165B2 (ja) * 2020-01-15 2025-07-16 国立大学法人大阪大学 認知症の予防又は治療剤
CN118767130A (zh) 2020-01-15 2024-10-15 国立大学法人大阪大学 糖尿病性自主神经障碍的预防或治疗剂
CN112138146B (zh) * 2020-09-25 2022-08-09 安徽医科大学 Manf蛋白的应用
AR124914A1 (es) 2021-02-18 2023-05-17 Mitsubishi Tanabe Pharma Corp Nuevo anticuerpo anti-pad4
AR130982A1 (es) 2022-11-07 2025-02-05 Univ Osaka Agente preventivo o terapéutico para enfermedades asociadas con la agregación de proteínas anormales
TW202523690A (zh) * 2023-09-29 2025-06-16 日商田邊三菱製藥股份有限公司 由脊髓或腦之障礙引起之疾病所伴隨之伴隨症狀之預防或治療劑

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5565331A (en) 1993-11-12 1996-10-15 The Regents Of The University Of California Nucleic acids encoding neural axon outgrowth modulators
US5747262A (en) 1995-10-16 1998-05-05 The Regents Of The University Of California Neurological drug screens
US5824775A (en) 1996-04-19 1998-10-20 The Regents Of The University Of California Human netrin-1
US5939271A (en) 1997-02-19 1999-08-17 The Regents Of The University Of California Netrin receptor
WO1999008533A1 (en) 1997-08-13 1999-02-25 Yale University Central nervous system axon regeneration
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
AU1837100A (en) 1998-11-30 2000-06-19 Millennium Pharmaceuticals, Inc. Netrin-like and ependymin-like nucleic acids and polypeptides and uses thereof
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
PT1176195E (pt) 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
US7166573B1 (en) 1999-05-28 2007-01-23 Ludwig Institute For Cancer Research Breast, gastric and prostate cancer associated antigens and uses therefor
DK2314686T4 (da) 2000-10-06 2023-08-21 Kyowa Kirin Co Ltd Celler, der danner antistofsammensætninger
ES2390425T3 (es) 2000-12-22 2012-11-12 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Uso de moléculas de orientación repulsivas (RGM) y sus moduladores
WO2002063959A1 (en) 2001-02-09 2002-08-22 The Schepens Eye Research Institute Methods and compositions for stimulating axon regeneration and prventing neuronal cell degeneration
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
AU2003234136A1 (en) 2002-04-18 2003-11-03 The General Hospital Corporation Drg11-responsive (dragon) gene family
US7771952B2 (en) * 2002-06-26 2010-08-10 Abott Laboratories Modulators and modulation of the interaction between RGM and Neogenin
US20040199186A1 (en) 2003-04-04 2004-10-07 Kuffler Suzanne Elizabeth Implant to promote axon regeneration across spinal cord and peripheral nerve gaps
AU2004279742A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Fused protein composition
CN1950108A (zh) * 2004-03-11 2007-04-18 生物线索株式会社 轴突再生促进剂
AU2005221471A1 (en) * 2004-03-11 2005-09-22 Bioclues, Inc Axon regeneration promoter
CA2573720A1 (en) 2004-07-14 2006-02-23 University Of Utah Research Foundation Netrin-related compositions and uses
US20060063208A1 (en) * 2004-08-02 2006-03-23 Woolf Clifford J DRG11-responsive (DRAGON) gene and uses thereof
US7449442B2 (en) 2005-07-12 2008-11-11 Children's Medical Center Corporation EGFR inhibitors promote axon regeneration
CN101277974A (zh) * 2005-09-30 2008-10-01 阿伯特有限及两合公司 排斥性引导分子(rgm)蛋白质家族的蛋白质的结合结构域及其功能性片段和它们的用途
US20080051319A1 (en) 2006-08-22 2008-02-28 Children's Medical Center Corporation Inhibiting JNK Signaling Promotes CNS Axon Regeneration
WO2008038599A1 (en) * 2006-09-25 2008-04-03 National University Corporation Chiba University Axonal regeneration promoter
EP1906185A1 (en) 2006-09-26 2008-04-02 ProteoSys AG Use of at least one isoform of progesterone receptor membrane component 1 (PGRMC1)
EP2033971A1 (de) 2007-09-06 2009-03-11 Abbott GmbH & Co. KG Bone Morphogenetic Protein (BMP)-bindende Domänen von Proteinen der Repulsive Guidance Molecule (RGM) Proteinfamilie und funktionale Fragmente davon sowie deren Verwendung
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
DE102008014880A1 (de) 2008-03-12 2009-09-17 Eberhard-Karls-Universität Tübingen Antientzündliches Polypeptid
US8470977B2 (en) * 2008-03-14 2013-06-25 Transgene S.A. Antibody against the CSF-1R
CN101306193A (zh) 2008-05-15 2008-11-19 复旦大学 人神经突起生长素在制备创伤愈合药物中的应用
AU2009255973B2 (en) 2008-06-06 2013-08-15 Children's Medical Center Corporation Promoting axon regeneration in the adult CNS through control of protein translation
JP2010146801A (ja) * 2008-12-17 2010-07-01 Kurita Water Ind Ltd 微生物発電方法及び微生物発電装置
KR20120118002A (ko) * 2009-12-08 2012-10-25 애보트 게엠베하 운트 콤파니 카게 망막 신경 섬유 층 변성의 치료에 사용하기 위한 ｒｇｍ ａ 단백질에 대한 모노클로날 항체
KR20170102378A (ko) 2009-12-09 2017-09-08 미쓰비시 타나베 파마 코퍼레이션 Ｔ 세포 활성화 저해제, 이것을 함유하는 의약 조성물 및 ｔ 세포 활성화 저해 물질의 스크리닝 방법
CN104144947B (zh) * 2011-12-14 2017-10-27 艾伯维德国有限责任两合公司 用于诊断和治疗铁相关病症的组合物和方法
EP3369746A1 (en) * 2012-01-27 2018-09-05 AbbVie Deutschland GmbH & Co KG Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
WO2013113107A1 (en) 2012-02-03 2013-08-08 University Health Network Methods for promoting neuron survival, axonal growth and/or regeneration
GB201203180D0 (en) * 2012-02-24 2012-04-11 Okapi Sciences Nv Compounds for treating parvovirus infection
US20140242043A1 (en) 2013-02-23 2014-08-28 Stemnion, Inc. Methods for preventing or treating optic neuritis
MD20180107A2 (ro) * 2013-03-18 2019-06-30 Biocerox Products B.V. Anticorpi anti-CD134 (OX40) umanizaţi şi utilizarea acestora
JP2016533318A (ja) 2013-09-17 2016-10-27 ユニバーシティ ヘルス ネットワーク （ユーエイチエヌ）： テクノロジー ディベロップメント アンド コマーシャリゼーション Ｒｇｍａ／ネオジェニンのシス相互作用又は脂質ラフトを標的とする剤及び治療方法における該剤の使用
WO2015120138A2 (en) 2014-02-05 2015-08-13 Dana-Farber Cancer Institute, Inc. AGENTS THAT MODULATE RGMb-NEOGENIN-BMP SIGNALING AND METHODS OF USE THEREOF
PE20180251A1 (es) 2015-04-28 2018-02-02 Mitsubishi Tanabe Pharma Corp PROTEINA DE UNIION A RGMa Y SU USO
CN105925578A (zh) 2016-05-30 2016-09-07 东北师范大学 靶向沉默Neogenin的shRNA
US20220089737A1 (en) * 2020-09-11 2022-03-24 Janssen Biotech, Inc. Multi-specific immune targeting molecules and uses thereof

Also Published As

Publication number Publication date
KR102613528B1 (ko) 2023-12-12
EP3290441A4 (en) 2018-10-17
CR20200517A (es) 2021-01-12
US20190270799A1 (en) 2019-09-05
TW201710296A (zh) 2017-03-16
CA2983898A1 (en) 2016-11-03
PE20230381A1 (es) 2023-03-06
JP2026032030A (ja) 2026-02-25
SI3290441T1 (sl) 2020-03-31
NZ775372A (en) 2024-12-20
JP2023025285A (ja) 2023-02-21
MX2017013894A (es) 2018-03-01
DOP2017000248A (es) 2018-01-31
LT3290441T (lt) 2020-02-10
HK1245808A1 (en) 2018-08-31
KR102451786B1 (ko) 2022-10-05
US20210277098A1 (en) 2021-09-09
RU2705304C2 (ru) 2019-11-06
IL287291B (en) 2022-09-01
BR112017022994A2 (pt) 2019-11-19
ZA201907773B (en) 2021-05-26
CR20170539A (es) 2018-04-20
HRP20192099T1 (hr) 2020-03-06
KR20230173734A (ko) 2023-12-27
PT3290441T (pt) 2019-12-02
JP6955721B2 (ja) 2021-10-27
JP2019141048A (ja) 2019-08-29
ZA201708047B (en) 2020-01-29
JP2023030057A (ja) 2023-03-07
US11008388B2 (en) 2021-05-18
IL255293B (en) 2021-10-31
CL2017002729A1 (es) 2018-06-08
KR102854388B1 (ko) 2025-09-02
TW202521584A (zh) 2025-06-01
NZ737770A (en) 2024-09-27
KR20220140023A (ko) 2022-10-17
TW202138389A (zh) 2021-10-16
KR20170138565A (ko) 2017-12-15
RU2017135353A (ru) 2019-04-08
MX392169B (es) 2025-03-21
EP3290441B1 (en) 2019-10-30
TW202328205A (zh) 2023-07-16
DK3290441T3 (da) 2020-01-02
CN107531791A (zh) 2018-01-02
PH12017501941A1 (en) 2018-03-19
NZ775384A (en) 2024-12-20
RU2019134410A (ru) 2020-03-03
JP6497760B2 (ja) 2019-04-10
JP2021106587A (ja) 2021-07-29
KR20190124350A (ko) 2019-11-04
JP2023120374A (ja) 2023-08-29
IL287291A (en) 2021-12-01
US10287346B2 (en) 2019-05-14
EP3584260A1 (en) 2019-12-25
CN113801225A (zh) 2021-12-17
TWI873576B (zh) 2025-02-21
SG11201708848TA (en) 2017-11-29
EP3290441A1 (en) 2018-03-07
CN107531791B (zh) 2021-09-07
CO2017011975A2 (es) 2018-02-20
JP2025029166A (ja) 2025-03-05
IL255293A0 (en) 2017-12-31
JP7606196B2 (ja) 2024-12-25
RU2017135353A3 (es) 2019-04-08
HUE047146T2 (hu) 2020-04-28
TWI732757B (zh) 2021-07-11
MX2022005565A (es) 2022-06-09
RS59847B1 (sr) 2020-02-28
AU2019210655A1 (en) 2019-08-22
GT201700224A (es) 2019-07-26
JPWO2016175236A1 (ja) 2018-04-19
PL3290441T3 (pl) 2020-05-18
ES2758480T3 (es) 2020-05-05
WO2016175236A1 (ja) 2016-11-03
JP7306660B2 (ja) 2023-07-11
SA517390230B1 (ar) 2021-06-09
US20180100012A1 (en) 2018-04-12
JP7307446B2 (ja) 2023-07-12
KR102040235B1 (ko) 2019-11-05
CY1122569T1 (el) 2021-01-27
AU2016253886A1 (en) 2017-12-14
JP7780158B2 (ja) 2025-12-04
TWI873350B (zh) 2025-02-21
AU2016253886B2 (en) 2019-05-16

Similar Documents

Publication Publication Date Title
DOP2017000248A (es) PROTEÍNA DE UNIÓN A RGMa Y SU USO
EA202091166A1 (ru) ПОЛИПЕПТИДЫ, СОДЕРЖАЩИЕ Fc С ИЗМЕНЕННЫМ ГЛИКОЗИЛИРОВАНИЕМ И СНИЖЕННОЙ ЭФФЕКТОРНОЙ ФУНКЦИЕЙ
EA201890169A1 (ru) Тау-связывающие антитела
MX386491B (es) Metodos para reducir los niveles de suero de agentes que contienen fc que usan antagonistas de fcrn.
CO7170123A2 (es) Complejo del factor viii con xten y proteína del factor von willebrand y sus usos
CL2020001262A1 (es) Plataforma de presentación en endosporas basadas en paenibacillus, productos y métodos relacionados.
UA118029C2 (uk) Модифіковане антитіло, що зв'язується з людським fcrn, й способи його застосування
CR20190594A (es) Receptores de células t novedosos, e inmunoterapia usando los mismos
CO6400232A2 (es) Proteína de enlace al receptores cgrp humano
EA201391632A1 (ru) Аминокислотные последовательности, направленные против il-17a, il-17f и/или il-17a/f, и содержащие их полипептиды
SA520412669B1 (ar) تصنيع ذيفانات عصبية ناتجة عن معاودة الارتباط الجيني من المطثية الوشيقية
EP2532365A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER
CO6180451A2 (es) Polipeptidos heterodimericos il -17 a/f y usos terapeuticos de los mismos
EP2532366A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF CANCER
AR079114A1 (es) Proteinas de enlace de antigenos anti-orai1 y usos de las mismas
PE20171336A1 (es) Anticuerpos contra tau y sus usos
WO2012159052A3 (en) Targeted delivery of proteins across the blood brain barrier
EA201590162A1 (ru) МУТАНТНЫЕ ФРАГМЕНТЫ OspA И СВЯЗАННЫЕ С НИМИ СПОСОБЫ И ПРИМЕНЕНИЕ
EA201691095A1 (ru) Мутантные фрагменты ospa и связанные с ними способы и применение
MX2020006586A (es) Metodos para potenciar la eliminacion de impurezas durante una cromatografia con proteina a.
CO6420322A2 (es) Anticuerpos anti-mst1r y usos de los mismos
WO2015108856A3 (en) Methods for enhancing the delivery of active agents
BR112013011285A2 (pt) vacina
UY33043A (es) Proteinas de enlace de antigenos anti-orai 1 y usos de las mismas
ES2429639B1 (es) Unión a glicosaminoglicanos de proteínas con dominio SECRET codificadas por poxvirus